Powered by lexis nexis

3D Signatures announces initiation of Hodgkin's lymphoma validation program

Feb 23, 2017 - Marketline Newswire

3D Signatures Inc. has announced the initiation of validation program for its Hodgkin's lymphoma, or HL, test, or Telo-HL.

Telo-HL is powered by the Company's proprietary TeloView software platform. The purpose of Telo-HL is to stratify HL patients at the point of diagnosis into non-relapsing and relapsing patients so that relapsing patients may be considered for alternative treatments to standard chemotherapy at the beginning of their treatment process. There is currently no biomarker...